

**Application for authorisation in the European Union
of DAS-81419-2 soybean grain for all uses as for any
other soybean, excluding cultivation, according to
Articles 5 and 17 of Regulation (EC) No 1829/2003
on genetically modified food and feed**

EFSA-GMO-NL-2013-XX

Part VII

Summary

Data Protection

This application contains scientific data and other information which are protected in accordance with Art. 31 of Regulation (EC) No 1829/2003

© 2013 Dow AgroSciences LLC (All Rights Reserved)

This document is protected under copyright law. This document is for use only by the regulatory authority to which this has been submitted by the owners, and only in support of actions requested by the owners. Any other use of this material, without prior written consent of the owners, is strictly prohibited. By submitting this document, Dow AgroSciences LLC does not grant any party or entity any right or license to the information or intellectual property described in this document.

1. GENERAL INFORMATION

1.1 Details of application

a)	Member State of application The Netherlands.
b)	Application number EFSA-GMO-NL-2013-XX.
c)	Name of the product (commercial and other names) The development code for this genetically modified soybean is: DAS-81419-2. In countries where DAS-81419-2 will be cultivated, packages of this soybean will be marketed under the name of the variety, in association with the trademark (to be defined).
d)	Date of acknowledgement of valid application By EFSA: not available at the time of submission.

1.2 Applicant

a)	Name of applicant Dow AgroSciences LLC represented by Dow AgroSciences Ltd.
b)	Address of applicant Focal Point: Dow AgroSciences Ltd European Development Centre 2 nd Floor, 3B Park Square Milton Park, Abingdon Oxon OX14 4RN Dow AgroSciences LLC 9330 Zionsville Road Indianapolis, Indiana 46268-1054
c)	Name and address of the representative of the applicant established in the Union (if the applicant is not established in the Union) Dow AgroSciences Ltd European Development Centre 2 nd Floor, 3B Park Square Milton Park, Abingdon Oxon OX14 4RN

1.3 Scope of the application

a) GM food	
<input checked="" type="checkbox"/>	Food containing or consisting of GM plants
<input checked="" type="checkbox"/>	Food produced from GM plants or containing ingredients produced from GM plants
b) GM feed	
<input checked="" type="checkbox"/>	Feed containing or consisting of GM plants
<input checked="" type="checkbox"/>	Feed produced from GM plants or containing ingredients produced from GM plants
c) GM plants for food or feed use	
<input checked="" type="checkbox"/>	Products other than food and feed containing or consisting of GM plants with the exception of cultivation
<input type="checkbox"/>	Seeds and plant propagating material for cultivation in the EU

1.4. Is the product or the uses of the associated plant protection product(s) already authorised or subject to another authorisation procedure within the Union?

Yes <input type="checkbox"/>	No <input checked="" type="checkbox"/>
If yes, specify	

1.5 Has the GM plant been notified under Part B of Directive 2001/18/EC?

Yes <input type="checkbox"/>	No <input checked="" type="checkbox"/>
<p>If no, refer to risk analysis data on the basis of the elements of Part B of Directive 2001/18/EC</p> <p>The composition, expression, agronomic performance and environmental impact trials with DAS-81419-2 soybean have been performed at several locations in the US, in 2011, where soybean is commercially grown in order to gather data for the risk assessment.</p> <p>A summary of the conclusions of the risk analysis that demonstrate the safety of DAS-81419-2 soybean to humans, animals and to the environment, has been presented in the respective sections throughout this summary.</p>	

1.6 Has the GM plant or derived products been previously notified for marketing in the Union under Part C of Directive 2001/18/EC?

Yes <input type="checkbox"/>	No <input checked="" type="checkbox"/>
If yes, specify	

1.7 Has the product been notified in a third country either previously or simultaneously?

Yes <input checked="" type="checkbox"/>	No <input type="checkbox"/>
<p>If yes, specify the third country and provide a copy of the risk assessment conclusions, the date of the authorisation and the scope</p> <p>Notification of intent to commercialize DAS-81419-2 has been sent to US EPA, USDA, US FDA, Health Canada, Canadian Food Inspection Agency, and Argentina CONABIA and SENASA in 2012. Additional applications for commercialization of food and feed use are being prepared for other countries, such as Brazil, Mexico, Colombia, South Africa, Japan, Korea, Taiwan, Philippines, and will be submitted throughout 2013 and 2014.</p>	

1.8 General description of the product

a)	<p>Name of the recipient or parental plant and the intended function of the genetic modification</p> <p>DAS-81419-2 soybean was developed using <i>Agrobacterium</i> mediated transformation to stably incorporate the <i>cryIFv3</i>, <i>cryIAC</i>(synpro) and <i>pat</i> genes, expressing the Cry1F, Cry1Ac and PAT proteins. The expression of the Cry1F and Cry1Ac proteins in DAS-81419-2 soybeans provide resistance against lepidopteran chewing pests under field conditions and the <i>pat</i> gene is used as a selectable marker gene.</p>
b)	<p>Types of products planned to be placed on the market according to the authorisation applied for and any specific form in which the product must not be placed on the market (seeds, cut-flowers, vegetative parts, etc.) as a proposed condition of the authorisation applied for</p> <p>The scope of this application according to Articles 5 and 17 of Regulation (EC) No 1829/2003 on genetically modified food and feed includes all uses of DAS-81419-2 soybean grain equivalent to the uses of any other soybean grain.</p>
c)	<p>Intended use of the product and types of users</p> <p>DAS-81419-2 soybean grain will be traded and used in the E.U. in the same manner as current commercial soybean varieties and by the same operators currently involved in the trade and use of conventional soybean.</p>
d)	<p>Specific instructions and/or recommendations for use, storage and handling, including mandatory restrictions proposed as a condition of the authorisation applied for</p> <p>No specific conditions or instructions are warranted or required for the placing on the market of DAS-81419-2 soybean grain, for all uses as any other soybean grain. DAS-81419-2 is substantially equivalent to other soybean varieties except for its resistance against certain lepidopteran insect pests, which is a trait of agronomic interest. DAS-81419-2 was shown to be as safe and as nutritious as conventional soybean. Therefore DAS-81419-2 and derived products will be stored, packaged, transported, handled and used in the same manner as the commercial soybean products.</p>
e)	<p>If applicable, geographical areas within the EU to which the product is intended to be confined under the terms of the authorisation applied for</p> <p>DAS-81419-2 soybean grain, are suitable for import, processing and food and feed uses throughout the E.U.</p>

<p>f) Any type of environment to which the product is unsuited</p> <p>DAS-81419-2 soybean grain, are suitable for import, processing and food and feed uses throughout the E.U.</p>
<p>g) Any proposed packaging requirements</p> <p>DAS-81419-2 is substantially equivalent to conventional soybean varieties (except for its resistance against certain lepidopteran insect pests). Therefore, DAS-81419-2 and derived products will be used in the same manner as other soybean and no specific packaging is foreseen.</p>
<p>h) Any proposed labelling requirements in addition to those required by law and when necessary a proposal for specific labelling in accordance with Articles 13(2), (3) and 25(2)(c), (d) and 25(3) of Regulation (EC) No 1829/2003. In the case of GMO plants, food and/or feed containing or consisting of GMO plants, a proposal for labelling has to be included complying with the requirements of Annex IV, A(8) of Directive 2001/18/EC</p> <p>In accordance with Regulations (EC) No 1829/2003 and 1830/2003, a labelling threshold of 0.9 % is applied for the placing on the market of DAS-81419-2 grain and derived products.</p> <p>Operators shall be required to label products containing or consisting of DAS-81419-2 soybean grain with the words “genetically modified soybean” or “contains genetically modified soybean”, and shall be required to declare the unique identifier in the list of GMOs that have been used to constitute the mixture that contains or consists of this GMO.</p> <p>Operators shall be required to label foods and feeds derived from DAS-81419-2 soybean grain with the words “produced from genetically modified soybean”. In the case of products for which no list of ingredients exists, operators shall ensure that an indication that the food or feed product is produced from GMOs is transmitted in writing to the operator receiving the product.</p> <p>Operators handling or using DAS-81419-2 soybean grain and derived foods and feeds in the E.U. are required to be aware of the legal obligations regarding traceability and labelling of these products. Given that explicit requirements for the traceability and labelling of GMOs and derived foods and feeds are laid down in Regulations (EC) No 1829/2003 and 1830/2003, and that authorised foods and feeds shall be entered in the Community Register, operators in the food/feed chain will be fully aware of the traceability and labelling requirements for DAS-81419-2 soybean grain. Therefore, no further specific measures are to be taken by the applicant for DAS-81419-2 soybean grain.</p>
<p>i) Estimated potential demand</p> <p>(i) In the Union Comparable to that of conventional soybean.</p> <p>(ii) In export markets for EU supplies Not applicable.</p>
<p>j) Unique identifier in accordance with Regulation (EC) No 65/2004</p> <p>DAS-81419-2.</p>

1.9 Measures suggested by the applicant to take in case of unintended release or misuse as well as measures for disposal and treatment

Because this application is for consent to import and use DAS-81419-2 soybean grain, as any other soybean, not including the cultivation of DAS-81419-2 varieties, environmental release would be more likely to occur during import, storage and processing of DAS-81419-2 soybean grain. However, modern methods of grain handling minimise losses of grain, so there is little chance of germination of spilt grain resulting in the development of mature plants of DAS-81419-2 in the E.U. Moreover, in the event of incidental spillage, the establishment of volunteer plants would be unlikely, since soybean cannot survive without human assistance and is not capable of surviving as a weed. Although soybean seed can over-winter in mild conditions and can germinate the following year, the appearance of soybean in rotational fields is rare under European conditions. Soybean volunteers, if they occurred, would be killed by frost or could be easily controlled by the use of selective herbicides. Moreover, the information presented in this application established that DAS-81419-2 is unlikely to be different from other soybean and, therefore, is unlikely to pose any threat to the environment or to require special measures for its containment.

No specific conditions are warranted or required for the placing on the market of DAS-81419-2 soybean grain, for import, processing, or use for food and feed.

2. INFORMATION RELATING TO THE RECIPIENT OR (WHERE APPROPRIATE) PARENTAL PLANTS

2.1. Complete name

a)	Family name	Leguminosae.
b)	Genus	<i>Glycine</i> .
c)	Species	<i>Glycine max.</i>
d)	Subspecies	N/A.
e)	Cultivar/breeding line or strain	DAS-81419-2.
f)	Common name	Soybean.

2.2 Geographical distribution and cultivation of the plant, including the distribution within the Union

Soybean can only cross with other members of *Glycine* subgenus *Soja*. The potential for such gene flow is limited by geographic isolation and by the fact that

they are highly self-pollinating species. Wild soybean species are endemic in China, Korea, Japan, Taiwan and the former USSR, and do not exist naturally in the EU.

2.3 Information concerning reproduction

a) Mode(s) of reproduction
Soybean is considered a self-pollinated species, propagated commercially by seed.
b) Specific factors affecting reproduction
The seed will germinate when the soil temperature reaches 10°C and will emerge in a 5-7 day period under favourable conditions. In new areas of soybean production an inoculation with <i>Bradyrhizobium japonicum</i> is necessary, for optimum efficiency of the nodulated root system.
c) Generation time
From seeding to maturity, soybean passes through various growth stages (e.g., germination — seedling stage, third true-leaf stage); the entire growing period is 120–140 days.

2.4 Sexual compatibility with other cultivated or wild plant species

Gene transfer between cultivated soybean and wild species of subgenus *Soja* may occur, but not in Europe, where the wild relatives of subgenus *Soja* are not present.

2.5 Survivability

a) Ability to form structures for survival or dormancy
Cultivated soybean seed rarely displays any dormancy characteristics and only under certain environmental conditions grows as a volunteer in the year following cultivation.
b) Specific factors affecting survivability
Soybean is a quantitative short day plant and hence flowers more quickly under short days. As a result, photoperiodism and temperature response are important in determining areas of cultivar adaptation.

2.6 Dissemination

a) Ways and extent of dissemination
Soybean is considered a self-pollinated species, propagated commercially by seed.
b) Specific factors affecting dissemination
The soybean flower stigma is receptive to pollen approximately 24 hours before anthesis and remains receptive 48 hours after anthesis. The anthers mature in the bud and directly pollinate the stigma of the same flower. As a result, soybeans exhibit a high percentage of self-fertilisation, and cross pollination is usually less than one percent.

2.7 Geographical distribution within the Union of the sexually compatible species

Soybean can only cross with other members of *Glycine* subgenus *Soja*. The potential for such gene flow is limited by geographic isolation and by the fact that they are highly self-pollinating species. Wild soybean species are endemic in China, Korea, Japan, Taiwan and the former USSR, and do not exist naturally in the EU.

In addition small amounts of soybean are commercially produced within Europe with Italy producing the highest amount at approximately 160,000 hectares in 2010, followed by France producing 50,000 hectares and Hungary producing 40,000 hectares.

2.8 In the case of plant species not normally grown in the Member State(s), description of the natural habitat of the plant, including information on natural predators, parasites, competitors and symbionts

Soybeans are grown in the EU commercially.

2.9 Other potential interactions, relevant to the GM plant, of the plant with organisms in the ecosystem where it is usually grown, or used elsewhere, including information on toxic effects on humans, animals and other organisms

Soybean it has a history of safe use for human food and animal feed. However, soybean is known to interact with other organisms in the environment including insects, birds and mammals. It is susceptible to a range of fungal diseases and nematode, insect and mite pests.

3. MOLECULAR CHARACTERISATION

3.1 Information relating to the genetic modification

a) Description of the methods used for the genetic modification

DAS-81419-2 soybean was developed using *Agrobacterium* mediated transformation to stably incorporate the *cryIFv3*, *cryIAc*(synpro) and *pat* genes, expressing the Cry1F, Cry1Ac and PAT proteins. The expression of the Cry1F and Cry1Ac proteins in DAS-81419-2 soybeans provide resistance against lepidopteran chewing pests under field conditions and the *pat* gene is used as a selectable marker gene.

b) Nature and source of the vector used

DAS-81419-2 has been obtained by conventional breeding of DAS-68416-4 and MON-89788-1 and no vector has been used to produce this soybean hybrid.

c) Source of donor DNA used for transformation, size and intended function of each constituent fragment of the region intended for insertion

The individual components and the function of these inherited DNA sequences are given in Table 1.

Table 1. Genetic elements in DAS-81419-2 soybean

Part VII - Summary

Feature Name	Feature Start	Feature Stop	Feature Length	Description
5' Flanking border	1	1297	1297	Soybean genomic DNA flanking the 5' end of the insert in DAS-81419-2 soybean
Re-arranged sequence	1298	1321	24	Re-arranged DNA fragment at the 5' end of the insert
<i>cryIAc(synpro)</i> partial fragment	1322	1419	98	Complementary <i>cryIAc(synpro)</i> partial fragment at the 5' end of the insert that is 99% identical to 1990-2087 bp of the full-length <i>cryIAc(synpro)</i> gene
Re-arranged sequence	1420	1432	13	Re-arranged DNA fragment at the 5' end of the insert
Partial T-DNA Border B	1433	1433	1	Last nucleotide from T-DNA Border B which is required for transfer of DNA from <i>Agrobacterium tumefaciens</i> into plant cells
Intervening sequence	1434	1704	271	Non-specific DNA sequences necessary for cloning
AtUbi10 promoter	1705	3026	1322	AtUbi10 promoter along with the 5' untranslated region and intron from <i>Arabidopsis thaliana</i> polyubiquitin 10 (UBQ10) gene
Intervening sequence	3027	3034	8	Non-specific DNA sequences necessary for cloning
<i>cryIF v3</i>	3035	6481	3447	<i>cryIF v3</i> (synthetic version of the <i>cryIF</i> gene from <i>Bacillus thuringiensis</i> subsp. <i>aizawai</i> strain PS811)
Intervening sequence	6482	6583	102	Non-specific DNA sequences necessary for cloning
AtuORF23 3' UTR	6584	7040	457	AtuORF23 3' UTR (3' untranslated region (UTR) comprising the transcriptional terminator and polyadenylation site of open reading frame 23 (ORF23) of <i>Agrobacterium tumefaciens</i> pTi15955
Intervening sequence	7041	7103	63	Non-specific DNA sequences necessary for cloning
CsVMV promoter	7104	7620	517	CsVMV promoter along with the 5' untranslated region derived from Cassava Vein Mosaic virus
Intervening sequence	7621	7629	9	Non-specific DNA sequences necessary for cloning
<i>cryIAc(synpro)</i>	7630	11100	3471	<i>cryIAc(synpro)</i> (synthetic version of the <i>cryIAc</i> gene from <i>Bacillus thuringiensis</i> subsp. <i>kurstaki</i> strain HD73)
Intervening sequence	11101	11133	33	Non-specific DNA sequences necessary for cloning
AtuORF23 3' UTR	11134	11590	457	AtuORF23 3' UTR (3' untranslated region (UTR) comprising the transcriptional terminator and polyadenylation site of open reading frame 23 (ORF23) of <i>Agrobacterium tumefaciens</i> pTi15955)
Intervening sequence	11591	11704	114	Non-specific DNA sequences necessary for cloning

CsVMV promoter	11705	12221	517	CsVMV promoter along with the 5' untranslated region derived from Cassava Vein Mosaic virus
Intervening sequence	12222	12228	7	Non-specific DNA sequences necessary for cloning
<i>pat</i>	12229	12780	552	<i>pat</i> (synthetic version of phosphinothricin acetyl transferase gene from <i>Streptomyces viridochromogenes</i>)
Intervening sequence	12781	12882	102	Non-specific DNA sequences necessary for cloning
AtuORF1 3' UTR	12883	13586	704	AtuORF1 3' UTR (3' untranslated region (UTR) comprising the transcriptional terminator and polyadenylation site of open reading frame 1 (ORF1) of <i>Agrobacterium tumefaciens</i> pTi15955)
Intervening sequence	13587	13784	198	Non-specific DNA sequences necessary for cloning
Re-arranged sequence	13785	13793	9	Re-arranged DNA fragment at the 3' end of the insert
3' Flanking border	13794	15172	1379	Soybean genomic DNA flanking the 3' end of the insert in DAS-81419-2 soybean

3.2 Information relating to the GM plant

3.2.1 Description of the trait(s) and characteristics which have been introduced or modified

DAS-81419-2 soybean expresses the Cry1F, Cry1Ac and PAT proteins, derived from *B. thuringiensis* subsps. *aizawai* & *berliner* and *Streptomyces viridochromogenes* providing resistance against certain lepidopteran chewing insect pests.

Commercialisation of DAS-81419-2 will therefore provide substantial benefits to growers by limiting yield losses from insect pressure.

3.2.2 Information on the sequences actually inserted or deleted

<p>a) The copy number of all detectable inserts, both complete and partial</p>	<p>The genome of DAS-81419-2 contains one insert as confirmed through Southern blot analysis.</p>
<p>b) In case of deletion(s), size and function of the deleted region(s)</p>	<p>A 57 bp deletion at the insertion locus occurred as a result of the T-DNA integration. According to currently available sequence information, no indication of endogenous gene or regulatory element disruption or deletion is present at the integration.</p>
<p>c) Sub-cellular location(s) of insert(s) (nucleus, chloroplasts, mitochondria, or maintained in a non-integrated form), and methods for its determination</p>	<p>DAS-81419-2 contains the single insert.</p>
<p>d) The organisation of the inserted genetic material at the insertion site</p>	<p>The resulting sequence analysis revealed that an intact T-DNA insert including a single copy of each of the <i>cryIFv3</i>, <i>cry1Ac</i>(synpro) and <i>pat</i> PTUs derived from</p>

<p>plasmid pDAB9582, has been integrated into DAS-81419-2 soybean.</p>
<p>(e) In case of modifications other than insertion or deletion, describe function of the modified genetic material before and after the modification as well as direct changes in expression of genes as a result of the modification</p> <p>Not Applicable.</p>

3.2.3 Information on the expression of the insert

<p>a) Information on developmental expression of the insert during the life cycle of the plant</p> <p>The levels of the Cry1F, Cry1Ac and PAT proteins in various tissues of DAS-81419-2 were assessed by validated enzyme-linked immunosorbent assays (ELISA).</p> <p>A field expression study was conducted at ten locations in U.S. during 2011. Ten sites were planted with DAS-81419-2 soybean and the non-transgenic control (Maverick). The test sites represented regions of diverse agronomic practices and environmental conditions for soybean in North America.</p> <p>The data show that the expression of the Cry1F, Cry1Ac and PAT proteins throughout key developmental stages of DAS-81419-2 soybean.</p>
<p>b) Parts of the plant where the insert is expressed</p> <p>Results of the analyses confirm expression of the Cry1F, Cry1Ac and PAT proteins throughout the tissues of DAS-81419-2.</p>

3.2.4. Genetic stability of the insert and phenotypic stability of the GM plant

<p>Based on the molecular characterisation of DAS-81419-2, it is highly likely that the insert sequences of DAS-81419-2 are conserved with their inherent properties.</p>

3.2.5 Information on how the GM plant differs from the recipient plant in

<p>a) Mode(s) and/or rate of reproduction</p> <p>Agronomic data collected from trials performed with DAS-81419-2 have demonstrated that DAS-81419-2 has not been altered in survival, multiplication or dissemination characteristics when compared to conventional soybean varieties. The trait for insect resistance has no influence on soybean reproductive morphology and hence no changes in seed dissemination would be expected.</p>
<p>b) Dissemination</p> <p>The inherited traits have no influence on soybean reproductive morphology and hence no changes in seed dissemination are to be expected.</p>
<p>c) Survivability</p> <p>Soybean is known to be a weak competitor in the wild, which cannot survive outside cultivation without human intervention. Field observations have demonstrated that DAS-81419-2 has not been altered in its survivability when compared to conventional soybean.</p>
<p>d) Other differences</p> <p>Comparative assessments in the field did not reveal any biologically significant differences between DAS-81419-2 and conventional soybean varieties, except for</p>

the introduced trait that is of agronomic interest.

3.2.6 Any change to the ability of the GM plant to transfer genetic material to other organisms

a) Plant to bacteria gene transfer

None of the genetic elements inserted in DAS-81419-2 have a genetic transfer function. Therefore, no changes are expected in the ability of these soybean lines to transfer genetic material to bacteria.

b) Plant to plant gene transfer

Not applicable. The scope of the current application does not include the cultivation of DAS-81419-2 varieties in the E.U.

4 COMPARATIVE ANALYSIS

4.1 Choice of the conventional counterpart and additional comparators

DAS-81419-2 was compared with a conventional control soybean with similar genetic background, as well as with other commercially available soybean varieties.

4.2 Experimental design and statistical analysis of data from field trials for comparative analysis

DAS-81419-2 and the conventional control soybean were grown at ten field sites in major soybean-growing areas of the U.S.A. during the 2011 field season.

The compositional study compared DAS-81419-2 to the non-transgenic near-isogenic control soybean Maverick. Reference lines were grown in the same field locations and under the same conditions as the test and control. Where statistical differences occurred, the measured analyte was compared to reference ranges and ranges reported in literature.

4.3 Selection of material and compounds for analysis

The numerous compounds that were selected for analysis in the compositional study were chosen on the basis of internationally accepted guidance provided by the OECD (*See* consensus document for compositional analysis of soybean), in addition to other selected compounds.

Based on the results of these extensive, compositional analyses conducted for DAS-81419-2 compared to conventional soybean varieties, there is no indication to further analyse other selected compounds in this soybean.

4.4 Comparative analysis of agronomic and phenotypic characteristics

Field trials with DAS-81419-2 were performed and the set of agronomic observations supports a conclusion that from an agronomic and phenotypic (morphological) point of view, DAS-81419-2 is equivalent to conventional soybean, except for its resistance against certain lepidopteran pests.

4.5 Effect of processing

Soybean is converted into a diverse range of food and feed products and derivatives used as food and feed ingredients or additives. As DAS-81419-2 is substantially equivalent and as safe and as nutritious as conventional soybean, the use of DAS-81419-2 soybean grain for the production of foods and feeds is no different from that of conventional soybean. Consequently, any effects of the production and processing of DAS-81419-2

soybean grain are not expected to be any different from the production and processing of the equivalent foods and feeds, originating from conventional soybean.

5 TOXICOLOGY

a)	Toxicological testing of newly expressed proteins
	<p>DAS-81419-2 expresses the Cry1F, Cry1Ac and PAT proteins. The conclusion of safety to humans of these proteins was based upon the following considerations:</p> <ul style="list-style-type: none"> • The proteins have a history of safe use; • They have no structural similarity to known toxins or other biologically active proteins that could cause adverse effects in humans or animals; • They do not exert any acute toxicity to mammals. <p>In addition, their low concentration in tissues that are consumed and their rapid digestibility in simulated digestive fluids provide additional assurance for their safety.</p> <p>It is therefore highly unlikely that the Cry1F, Cry1Ac and PAT proteins would cause any toxic effects on human or animal health.</p>
b)	Testing of new constituents other than proteins
	<p>Since soybean is known as a common source of food and feed with a centuries-long history of safe use and consumption around the world and as DAS-81419-2 was shown to be substantially equivalent to conventional soybean, no testing of any constituent other than the inherited proteins are indicated.</p>
c)	Information on natural food and feed constituents
	<p>Soybean is known as a common source of food and feed with a centuries-long history of safe use and consumption around the world. No particular natural constituents of soybean are considered to be of significant concern to require additional information or further risk assessment.</p>
d)	Testing of the whole GM food/feed
	<p>Evaluation of the nutrient composition of DAS-81419-2 soybean proved its equivalency to non-GM control soybean with comparable genetic background and to representative commercial lines. In addition it's been shown that the Cry1F, Cry1Ac and PAT proteins expressed in DAS-81419-2 soybean are safe for humans, animal health and the environment. On that basis, no additional studies are required.</p>

6. ALLERGENICITY

a)	Assessment of allergenicity of the newly expressed protein
	<p>The Cry1F, Cry1Ac and PAT proteins have been assessed for their potential allergenicity according to the recommendations of Codex Alimentarius Commission. The proteins are from non-allergenic sources, lack structural similarity to known allergens, are rapidly digested in simulated gastric fluid, are not glycosylated and constitute a very small portion of the total protein present in the grain of DAS-81419-2. Taken together, these data lead to the conclusion that the Cry1F, Cry1Ac and PAT proteins are unlikely to have any allergenic potential; hence, DAS-81419-2 is as safe as conventional soybean regarding the risk for allergenicity.</p>

b) Assessment of allergenicity of the whole GM plant

Compositional analyses, comparative phenotypic assessments and animal feeding studies have demonstrated that DAS-81419-2 is substantially equivalent to traditional soybean, with the exception of the Cry1F, Cry1Ac and PAT proteins (which are unlikely to have any allergenic potential).

7. NUTRITIONAL ASSESSMENT

a) Nutritional assessment of GM food

The introduced traits in DAS-81419-2 are of agronomic interest, and are not intended to change any nutritional aspects of this soybean. Hence this soybean is not expected to be more or less attractive for use as food (or feed), for processing, or as a food (or feed) ingredient. Therefore, anticipated dietary intake of soybean-derived foods and feeds is not expected to be altered upon commercialisation of DAS-81419-2 soybean grain, and no nutritional imbalances are expected as a result of the use of DAS-81419-2 soybean grain.

b) Nutritional assessment of GM feed

As discussed throughout this application, animal feed products from DAS-81419-2 soybean are substantially equivalent to, nutritionally equivalent to, and as safe as feed commercial soybean.

8. EXPOSURE ASSESSMENT – ANTICIPATED INTAKE/EXTENT OF USE

There are no anticipated changes in the intake and/or extent of use of soybean or derived products for use as such or in food or feed as a result of the addition of DAS-81419-2 soybean grain to the conventional soybean supply. DAS-81419-2 soybean grain is expected to replace a portion of current soybean varieties such that their intake or use will represent some fraction of the total products derived from soybean.

9. RISK CHARACTERISATION FOR THE SAFETY ASSESSMENT OF GM FOOD AND FEED

Assessments show that DAS-81419-2 demonstrates agronomic, phenotypic and compositional equivalence to non-transgenic soybean. It has also been established that it is highly unlikely that Cry1F, Cry1Ac and PAT proteins will be toxic or allergenic making the risk negligible that DAS-81419-2 will cause adverse effects in humans or animals.

10. POST-MARKET MONITORING ON GM FOOD/FEED

The assessment of the human and animal safety of DAS-81419-2 was conducted on the basis of its substantial equivalence to conventional soybean (except for the introduced traits) and by extensive characterisation of the introduced traits, which are of agronomic interest, resulting in the expression of the Cry1F, Cry1Ac and PAT proteins.

The pre-market risk characterisation for food and feed use of DAS-81419-2 demonstrates that the risks of consumption of DAS-81419-2 or its derived products are consistently negligible and no different from the risks associated with the consumption of conventional soybean and soybean-derived products.

As a consequence, specific risk management measures are not indicated, and post-market monitoring of the use of this soybean for food, feed or processing is neither

warranted, nor appropriate.

11.ENVIRONMENTAL ASSESSMENT

11.1 Mechanism of interaction between the GM plant and target organisms

DAS-81419-2 expresses the Cry1F, Cry1Ac and PAT proteins, which confer resistance to certain lepidopteran insect chewing pests.

A generalised mode of action of Cry proteins includes the following steps: ingestion of the protoxin crystal by the insect, solubilisation of the crystal in the insect midgut, proteolytic processing of the released Cry protein by digestive enzymes to produce an active toxin termed delta-endotoxin, binding of the endotoxin to receptors on the surface of midgut epithelial cells of target organisms, formation of membrane ion channels or pores, and consequent disruption of cellular homeostasis. Electrolyte imbalance and pH changes render the gut paralysed, which causes the insect to stop eating and die.

The likelihood that the import and use of DAS-81419-2 soybean grain for food, feed or processing will result in plants of these soybean lines being present in the environment is negligible.

11.2 Potential changes in the interactions of the GM plant with the biotic environment resulting from the genetic modification

a) Persistence and invasiveness

Like for conventional soybean, the likelihood of DAS-81419-2 spreading in the environment is negligible, as soybean is neither persistent nor invasive and these parameters are unaltered in DAS-81419-2 when compared to conventional soybean. In the unlikely event of the establishment of DAS-81419-2 plants in the environment, the introduced traits would confer only limited selective protection against lepidopteran pests - of short duration, narrow spatial context and with negligible consequences for the environment. Hence, the risk of establishment and spreading of DAS-81419-2 soybean grain into the environment is negligible.

b) Selective advantage or disadvantage

Compared with conventional soybean, the presence of the introduced traits in DAS-81419-2 would only confer a meaningful advantage under specific conditions, i.e. where target lepidopteran pest species would be present in sufficiently high numbers; if no other more important factors limiting its survival in the environment were present. This introduced “advantage” is only relevant in agricultural habitats (i.e. in soybean fields) and is short in duration. Hence, the risk of resistance against certain lepidopteran pests traits in DAS-81419-2, is negligible, as soybean is unlikely to establish outside cultivation under European conditions (see Section E.3.1). When viewed in the context of today’s baseline agronomic practices for the production of soybean, these advantages present negligible risk to the agricultural environment.

c) Potential for gene transfer

DAS-81419-2 is unchanged in its potential for gene transfer compared to conventional soybean. There is no potential for gene transfer from DAS-81419-2 to wild plant species in the E.U. and negligible likelihood for gene transfer to other soybean crops, as this application is not for consent to cultivate DAS-81419-2 varieties in the E.U. The environmental risk of potential gene transfer is negligible.

d) Interactions between the GM plant and target organisms

	<p>Since the likelihood is negligible that the import, processing and food and feed use of DAS-81419-2 will result in plants of this soybean being present in the environment at meaningful levels, it is not expected that organisms will be exposed to the Cry1F, Cry1Ac and PAT proteins.</p>
e)	<p>Interactions of the GM plant with non-target organisms</p> <p>Given the scope of the current application, which does not include the cultivation of DAS-81419-2 varieties in the E.U., the likelihood for direct or indirect interactions of these soybean lines with non-target organisms is considered to be negligible. In addition, the newly expressed proteins present a negligible hazard to non-target organisms, even if incidental spillage of DAS-81419-2 grain during import, storage, transport or use would lead to the short survival of DAS-81419-2 plants in the environment. As a consequence, there is negligible risk for harmful effects of DAS-81419-2 on non-target organisms, either through direct or indirect interactions with this soybean or through contact with the newly expressed protein.</p> <p>Furthermore, no adverse effects were brought forward by the people handling these products during the field trials conducted in the U.S.A.</p>
f)	<p>Effects on human health</p> <p>The likelihood for any adverse effects occurring in humans as a result of their contact with this soybean is no different from conventional soybean. DAS-81419-2 expresses the Cry1F, Cry1Ac and PAT proteins, which have negligible potential to cause any toxic or allergenic effects in humans. Therefore, the risk of changes in the occupational health aspects of this soybean is negligible.</p>
g)	<p>Effects on animal health</p> <p>The likelihood of potential adverse effects in animals fed on DAS-81419-2 and in humans, consuming those animals, is negligible. Therefore, the risk of DAS-81419-2 to the feed/food chain is also negligible.</p>
h)	<p>Effects on biogeochemical processes</p> <p>There is no evidence that DAS-81419-2 plants would be any different from conventional soybean regarding their direct influence on biogeochemical processes or nutrient levels in the soil, as DAS-81419-2 is compositionally equivalent and has equivalent growth and development to conventional soybean.</p>
i)	<p>Impacts of the specific cultivation, management and harvesting techniques</p> <p>Not applicable. This application is for consent to import DAS-81419-2 soybean grain in the E.U. and for the use of these soybean lines as any other soybean, excluding the cultivation of varieties in the E.U.</p>

11.3 Potential interactions with the abiotic environment

No adverse impact of DAS-81419-2 on the abiotic environment is expected to result from the import, processing or use of this product for food and feed in the E.U. Although the Cry1F, Cry1Ac and PAT proteins are introduced proteins in soybean, they already have a safe history and have no known negative interactions with the abiotic environment. The *Bacillus thuringiensis* and *Streptomyces viridochromogenes* from which the Cry1F, Cry1Ac and PAT proteins are derived are widespread in nature and found all over the world. These proteins are innocuous, except for the insect species they control, and belong to a class of enzymes that are ubiquitous in nature. The families of the Cry1F, Cry1Ac and PAT proteins have no known negative interactions with the abiotic environment.

11.4 Risk characterisation for the environmental risk assessment

Considering the scope of this application is for import for food and feed uses of DAS-81419-2 and that cultivation of DAS-81419-2 soybean varieties in the EU is not planned; any exposure to the environment from the import of DAS-81419-2 soybean will be limited to unintended release via spillage during transportation of the grain. Therefore, the likelihood that the import and use of DAS-81419-2 for food, feed or processing will result in plants of this soybean being present in the environment is negligible.

12. ENVIRONMENTAL MONITORING PLAN

a)	<p>General (risk assessment, background information)</p> <p>As required by Article 5(5)(b) and 17(5)(b) of Regulation (EC) No 1829/2003 the proposed monitoring plan for DAS-81419-2 has been developed according to the principles and objectives outlined in Annex VII of Directive 2001/18/EC and Decision 2002/811/EC establishing guidance notes supplementing Annex VII to Directive 2001/18/EC. The structure of the monitoring plan also takes into account the guidance on presentation of applications provided in the Guidance Document of the Scientific Panel on Genetically Modified Organisms for the risk assessment of genetically modified plants and derived food and feed.</p>
b)	<p>Interplay between environmental risk assessment and monitoring</p> <p>An environmental risk assessment (e.r.a.) was carried out for DAS-81419-2 according to the principles laid down in Annex II to Directive 2001/18/EC and Decision 2002/623/EC establishing guidance notes supplementing Annex II to Directive 2001/18/EC. The scientific evaluation of the characteristics of DAS-81419-2 in the e.r.a. (Section E.3) has shown that the risk for potential adverse effects on human and animal health or the environment is negligible in the context of the intended uses of DAS-81419-2 soybean grain.</p>
c)	<p>Case-specific GM plant monitoring (approach, strategy, method and analysis)</p> <p>The scientific evaluation of the characteristics of DAS-81419-2 in the e.r.a. has shown that the risk for potential adverse effects on human and animal health or the environment is negligible in the context of the intended uses. It is therefore considered that there is no need for case-specific monitoring.</p>
d)	<p>General surveillance of the impact of the GM plant (approach, strategy, method and analysis)</p> <p>In accordance with Council Decision 2002/811/EC, general surveillance is not based on a particular hypothesis and it should be used to identify the occurrence of unanticipated adverse effects of the viable GMO or its use for human and animal health or the environment that were not predicted in the e.r.a.</p> <p>The authorisation holders are not involved in commodity trade with DAS-81419-2 soybean grain. The monitoring methodology hence needs to be predominantly based on collaboration with third parties, such as operators involved in the import, handling and processing of viable DAS-81419-2 soybean grain. They are exposed to the imported viable DAS-81419-2 soybean grain and therefore are the best placed to observe and report any unanticipated adverse effects in the framework of their routine surveillance of the commodities they handle and use.</p> <p>The general surveillance information reported to and collected by the authorisation holders from the European trade associations or other sources will be analysed for its relevance. Where information indicates the possibility of an unanticipated</p>

adverse effect, the authorisation holder will immediately investigate to determine and confirm whether a significant correlation between the effect and DAS-81419-2 soybean grain can be established. If the investigation establishes that DAS-81419-2 soybean grain was present when the adverse effect was identified, and confirms that DAS-81419-2 soybean grain is the cause of the adverse effect, the authorisation holders will immediately inform the European Commission, as described in Section E.4.3.4.

e) Reporting the results of the monitoring

The authorisation holders will submit an annual monitoring report containing information obtained from participating networks, and/or in case of an effect that was confirmed. If information that confirms an adverse effect which alters the existing risk assessment becomes available, Dow AgroSciences LLC will submit a report, consisting of a scientific evaluation of the potential adverse effect and a conclusion on the safety of the product. The report will also include, where appropriate, the measures that were taken to ensure the safety of human or livestock health and/or the environment.

13. DETECTION AND EVENT-SPECIFIC IDENTIFICATION TECHNIQUES FOR THE GM PLANT

The PCR detection method to confirm the molecular identity of DAS-81419-2 soybean along with complementary information and samples of DAS-81419-2 soybean and non-GM soybean have been provided to the JRC-IHCP (Joint Research Centre-Institute of Health and Consumer Protection).

The Institute for Reference Materials and Measurements (IRMM) is collaborating with Dow AgroSciences to develop certified reference materials for DAS-81419-2 soybean. The sales conditions of certified reference materials will be available from the IRMM website (<http://irmm.jrc.ec.europa.eu/html/homepage.htm>). Detailed information on these materials is given in the IRMM.

14 INFORMATION RELATING TO PREVIOUS RELEASES OF THE GM PLANT

14.1 History of previous releases of the GM plant notified under Part B of the Directive 2001/18/EC and under Part B of Directive 90/220/EEC by the same notifier

a)	Notification number None
b)	Conclusions of post-release monitoring N/A
c)	Results of the release in respect to any risk to human health and the environment (submitted to the Competent Authority according to Article 10 of Directive 2001/18/EC) N/A

14.2 History of previous releases of the GM plant carried out outside the Union by the same notifier

a)	Release country DAS-81419-2 has been field tested in the US in 2009, 2010, 2011 and 2012. It has
-----------	--

	also been field tested in Argentina and Brazil beginning 2011.
b) Authority overseeing the release	<p>US: United States Department of Agriculture (USDA)</p> <p>Argentina: Secretary of Agriculture with the advice of the National Advisory Commission on Agricultural Biotechnology (CONABIA for its name in Spanish)</p> <p>Brazil: Ministry of Science and Technology, the National Technical Biosafety Commission (CTNBio)</p>
c) Release site	<p>US: Multiple sites in soybean producing states of the US</p> <p>Argentina: Multiple sites in soybean producing regions of Argentina</p> <p>Brazil: Multiple sites in soybean producing regions of Brazil.</p>
d) Aim of the release	<p>US: assess agronomic performance, efficacy, variety evaluation, seed production, yield, and collect regulatory data.</p> <p>Argentina: assess performance, efficacy, agrophenotypic characteristics, and impact on non-target organism (NTO).</p> <p>Brazil: assess performance, efficacy, variety evaluation, yield, and collection of regulatory data..</p>
e) Duration of the release	12 months per release
f) Aim of post-releases monitoring	Assessment/removal of volunteers
g) Duration of post-releases monitoring	12 months per release.
h) Conclusions of post-release monitoring	Volunteers have been eliminated to prevent potential persistence in the environment.
i) Results of the release in respect to any risk to human health and the environment	No evidence that DAS-81419-2 is likely to cause any adverse effects to human or animal health or the environment.

7.5 *Product specification*

DAS-81419-2 soybean grain will be imported into the E.U. in mixed shipments of soybean grain and products, produced in other world areas, for use by operators that have traditionally been involved in the commerce, processing and use of soybean and soybean derived products in the E.U.

3. **Links (some of these links may be accessible only to the competent authorities of the Member States, to the Commission and to EFSA):**

a)	Status/process of approval The EFSA website ¹ provides information related to the applications submitted under Regulation (EC) No 1829/2003 on genetically modified food and feed.
b)	Assessment Report of the Competent Authority (Directive 2001/18/EC) A notification for DAS-81419-2 according to Part C of Directive 2001/18/EC has not been submitted by Dow AgroSciences Europe.
c)	EFSA opinion An EFSA opinion, specifically for DAS-81419-2, was not available at the time of submission of this application.
d)	Commission Register (Commission Decision 2004/204/EC) Once authorised, food and feed products will be entered in the Community Register of GM food and feed ² .
e)	Molecular Register of the Community Reference Laboratory/Joint Research Centre Information on detection protocols can be found on the JRC website ³ .
f)	Biosafety Clearing-House (Council Decision 2002/628/EC) The publicly accessible portal site of the Biosafety Clearing-House (BCH) can be found at http://bch.biodiv.org/ .
g)	Summary Notification Information Format (SNIF) (Council Decision 2002/812/EC) A notification and SNIF according to Directives 2001/18/EC and 2002/812/EC, respectively, have not been submitted for DAS-81419-2. The EFSA website ⁴ does provide a link to this summary of the application for DAS-81419-2 under Regulation (EC) No 1829/2003.

¹ http://www.efsa.europa.eu/EFSA/ScientificPanels/GMO/efsa_locale-1178620753812_GMOApplications.htm

² http://europa.eu.int/comm/food/dyna/gm_register/index_en.cfm

³ <http://gmo-crl.jrc.it/statusof doss.htm>

⁴ http://www.efsa.europa.eu/EFSA/ScientificPanels/GMO/efsa_locale-1178620753812_GMOApplications.htm